Biotech Values

[DonShimoda]

If I'm not mistaken Pfizer's PF1066 is the only ALK inhibitor currently in clinical trial. The AACR abstracts are out and although it's only pre-clinical data, in a direct comparison with PF1066 "AP26113 exhibited ~100-fold selectivity for ALK-positive lines compared with a ~10-fold selectivity for PF1066. At the highest doses tested, strong regressions were achieved with AP26113, but not PF1066."

http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=70a76d65-6c78-4df3-91cc-af1e39942ea9&cKey=46d7d71e-b05e-4287-8e02-53a7f55339c1&mKey={0591FA3B-AFEF-49D2-8E65-55F41EE8117E}